US Patent Issued to Neutrolis on March 3 for "Engineered DNASE enzymes for thrombosis therapy" (Massachusetts Inventors)

ALEXANDRIA, Va., March 3 -- United States Patent no. 12,565,642, issued on March 3, was assigned to Neutrolis Inc. (Cambridge, Mass.).

"Engineered DNASE enzymes for thrombosis therapy" was invented by Tobias A. Fuchs (Cambridge, Mass.) and Abdul Hakkim R. (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (D1L2), DNASE1-LIKE 3 Isoform 1 (D1L3), DNASE1-LIKE 3 Isoform 2 (D1L3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In accordance with t...